Your browser doesn't support javascript.
loading
Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
Ribeiro, Tatiane Bomfim; Buss, Lewis; Wayant, Cole; Nobre, Moacyr Roberto Cuce.
Affiliation
  • Ribeiro TB; Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Buss L; Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Wayant C; Department of Biomedical Sciences, Oklahoma State University Center for Health Science, Tulsa, OK, United States of America.
  • Nobre MRC; Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
PLoS One ; 15(7): e0236345, 2020.
Article in En | MEDLINE | ID: mdl-32706800
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Drug Approval / Databases, Pharmaceutical / Lung Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2020 Document type: Article Affiliation country: Brazil Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Drug Approval / Databases, Pharmaceutical / Lung Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2020 Document type: Article Affiliation country: Brazil Country of publication: United States